Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study by Borggreve, A.S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/200332
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
STUDY PROTOCOL Open Access
Preoperative image-guided identification of
response to neoadjuvant
chemoradiotherapy in esophageal cancer
(PRIDE): a multicenter observational study
A. S. Borggreve1,2* , S. Mook2, M. Verheij3, V. E. M. Mul4, J. J. Bergman5, A. Bartels-Rutten6, L. C. ter Beek6,
R. G. H. Beets-Tan6, R. J. Bennink7, M. I. van Berge Henegouwen8, L. A. A. Brosens9, I. L. Defize1,2, J. M. van Dieren10,
H. Dijkstra11, R. van Hillegersberg2, M. C. Hulshof12, H. W. M. van Laarhoven13, M. G. E. H. Lam14,
A. L. H. M. W. van Lier1, C. T. Muijs4, W. B. Nagengast15, A. J. Nederveen7, W. Noordzij16, J. T. M. Plukker17,
P. S. N. van Rossum1, J. P. Ruurda2, J. W. van Sandick18, B. L. A. M. Weusten19, F. E. M. Voncken3, D. Yakar11,
G. J. Meijer1 and on behalf of the PRIDE study group
Abstract
Background: Nearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally advanced
esophageal cancer have a pathologic complete response (pCR) of the primary tumor upon histopathological
evaluation of the resection specimen. The primary aim of this study is to develop a model that predicts the
probability of pCR to nCRT in esophageal cancer, based on diffusion-weighted magnetic resonance imaging (DW-
MRI), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and 18F-fluorodeoxyglucose positron
emission tomography with computed tomography (18F-FDG PET-CT). Accurate response prediction could lead to a
patient-tailored approach with omission of surgery in the future in case of predicted pCR or additional neoadjuvant
treatment in case of non-pCR.
Methods: The PRIDE study is a prospective, single arm, observational multicenter study designed to develop a
multimodal prediction model for histopathological response to nCRT for esophageal cancer. A total of 200 patients
with locally advanced esophageal cancer - of which at least 130 patients with adenocarcinoma and at least 61
patients with squamous cell carcinoma - scheduled to receive nCRT followed by esophagectomy will be included.
The primary modalities to be incorporated in the prediction model are quantitative parameters derived from MRI
and 18F-FDG PET-CT scans, which will be acquired at fixed intervals before, during and after nCRT. Secondary
modalities include blood samples for analysis of the presence of circulating tumor DNA (ctDNA) at 3 time-points
(before, during and after nCRT), and an endoscopy with (random) bite-on-bite biopsies of the primary tumor site
and other suspected lesions in the esophagus as well as an endoscopic ultrasonography (EUS) with fine needle
aspiration of suspected lymph nodes after finishing nCRT. The main study endpoint is the performance of the
model for pCR prediction. Secondary endpoints include progression-free and overall survival.
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Discussion: If the multimodal PRIDE concept provides high predictive performance for pCR, the results of this
study will play an important role in accurate identification of esophageal cancer patients with a pCR to nCRT. These
patients might benefit from a patient-tailored approach with omission of surgery in the future. Vice versa, patients
with non-pCR might benefit from additional neoadjuvant treatment, or ineffective therapy could be stopped.
Trial registration: The article reports on a health care intervention on human participants and was prospectively
registered on March 22, 2018 under ClinicalTrials.gov Identifier: NCT03474341.
Keywords: Esophageal cancer, Neoadjuvant chemoradiotherapy, Pathologic complete response, Image-guided, MRI,
DW-MRI, DCE-MRI, PET-CT, ctDNA
Background
Esophageal cancer is the ninth most common type of can-
cer and the sixth most leading cause of cancer related death
[1]. Surgical resection has long been the standard curative
treatment for locally advanced esophageal cancer. However,
the poor survival rates of surgery alone prompted many
researchers to explore neoadjuvant therapy approaches to
improve survival. Randomized clinical trials have dem-
onstrated a consistent prognostic benefit of neoadju-
vant chemotherapy or chemoradiotherapy followed by
surgery over surgery alone for locally advanced esophageal
cancer [2–4]. In the Netherlands, this resulted in the
adoption of neoadjuvant chemoradiotherapy (nCRT) ac-
cording to the CROSS regimen followed by surgery as
standard of care [4].
Nearly one third of all esophageal cancer patients
(29%) treated with nCRT have no viable tumor cells de-
tected at the primary tumor site at histopathological
evaluation of the resection specimen, referred to as
pathologic complete response (pCR) [4]. It has been
argued that in patients who achieve a pCR, surgery may
be omitted without substantially reducing survival out-
comes. In fact, as an esophagectomy is associated with
substantial morbidity, mortality (up to 3–5%) and im-
paired quality of life [5–9], it can be speculated that
surgery may have a detrimental effect on these pa-
tients. Consequently, proper identification of patho-
logic complete responders prior to surgery could yield
an organ-preserving regimen avoiding esophagectomy
and its postoperative complications.
Reversely, 18% of patients have more than 50% vital
residual tumor cells in the primary tumor bed at histopath-
ology after nCRT and surgery, referred to as non-re-
sponders [4]. The CROSS regimen is associated with
grade ≥ 3 toxicity events according to the Common Ter-
minology Criteria for Adverse Events (CTCAE) in up to
13% of patients [4]. Thus, these non-responders are ex-
posed to side effects of nCRT probably without the benefits.
Therefore, early identification of the non-responders during
nCRT may be beneficial, as alternative treatment strategies
could be explored for this group, such as additional neoad-
juvant treatment, or ineffective therapy could be stopped.
Several diagnostic strategies have been proposed to
predict response and ultimately omit surgery in selected
patients. Computed tomography (CT) is used preferably
in initial staging of esophageal cancer, especially with
regard to the presence of distant metastases, but does
not satisfactorily restage after nCRT (accuracies ranging
from 51 to 75%) [10–12]. Remaining tumor tissue is
difficult to distinguish from therapy-induced peritumoral
fibrosis and inflammation. As such, CT tends to over-
stage the preoperative tumor status.
Endoscopic ultrasonography (EUS) with or without
biopsy has not yielded satisfactory results either. System-
atic reviews pointed out that the accuracy rates of EUS
for evaluating response to nCRT in esophageal cancer
were moderate to poor (27–78%) [10, 12, 13]. The
pooled sensitivity of EUS after nCRT for detection of
residual primary tumor in a meta-analysis including 11
studies was 96.4% (95%-CI: 91.7–98.5%), with a pooled
specificity of only 10.9% (95%-CI: 3.5–29.0%) [14]. Endo-
scopic biopsy after chemoradiotherapy for esophageal
cancer on the other hand was a very specific (pooled
estimate 91.0%, 95%-CI: 85.6–94.5%), but not a sensitive
method (pooled estimate 34.5%, 95%-CI: 26.0–44.1%) for
detection of residual primary tumor after nCRT, as re-
ported in a recent meta-analysis including 12 studies
[14]. Results from the recently published preSANO
study revealed that with bite-on-bite biopsies, the sensi-
tivity for the detection of residual disease increased sub-
stantially compared to regular biopsies (an increase from
54% [95%-CI: 38–70%] to 74% [95%-CI: 64–83%]) [15].
Moreover, promising results for response prediction were
obtained using repeated integrated 18F-fluorodeoxyglucose
positron emission tomography and computed tomography
(18F-FDG PET-CT), with accuracies ranging from 76 to
85% [14, 16–18]. The change in 18F-FDG uptake during
nCRT, reflecting a change in glucose metabolism by cancer
cells, may be used to identify these responders [19]. A sys-
tematic review on the value of these quantitative 18F-FDG
PET(-CT) measurements including 20 studies, showed that
response could be predicted with sensitivities ranging from
33 to 100% (pooled estimate of 67%) and specificities ran-
ging from 30 to 100% (pooled estimate of 68%) [19].
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This supports the concept that functional imaging
could play an important role in accurate response
prediction. In this light, magnetic resonance imaging
(MRI) has recently shown great potential for response
prediction to nCRT for esophageal cancer [20–23].
Diffusion-weighted MRI (DW-MRI) is a functional im-
aging modality that allows for tissue characterization by
deriving image contrast from restriction in the free
diffusion (i.e. random mobility or Brownian motion) of
water molecules, which is related to microstructural
tissue organization. An apparent diffusion coefficient
(ADC) map can be derived from the DW-MRI images
to quantify the diffusion restriction in a certain volume
of interest. The ADC is inversely correlated with tissue
cellularity. As chemoradiotherapy can result in the
loss of cell membrane integrity, tumor response can
be detected as an increase in tumor ADC. In two
exploratory studies, the treatment-induced relative
changes in ADC over time (ΔADC), during nCRT,
appeared highly predictive of histopathological re-
sponse [22, 24]. Using repeated DW-MRI only, a high
area under the receiver operating curve (AUCROC) was
attained for identifying pathologic complete responders
was attained [22, 24].
Dynamic contrast-enhanced magnetic resonance im-
aging (DCE-MRI), the acquisition of serial MR images
while intravenously administering a contrast agent,
provides further insight into the nature of the tissue
properties related to perfusion. Based on these images,
quantitative parameters such as the transfer constant
(Ktrans) and blood-normalized initial-area-under-the-
gadolinium-concentration curve (AUC) can be calcu-
lated. The AUC reflects blood flow, vascular permeability
and the fraction of interstitial space [16]. In a pilot study,
all pathologic complete responders showed a decrease in
AUC of 25% or more over the entire treatment course
(ΔAUC), whereas an increase in AUC during treatment
was observed for those patients who did not obtain a pCR
(p = 0.003) [18].
In addition to functional imaging, circulating tumor
cells and corresponding circulating tumor DNA (ctDNA)
have been proposed as noninvasive and real-time
biomarkers for predicting patient prognosis in esopha-
geal carcinomas [25–28]. Circulating tumor cells and
ctDNA are present in the blood vessels adjacent to the
tumor, and are subsequently transported throughout
the body via the circulation [27]. As such, ctDNA
reflects the presence of disease and could provide
valuable information on the response to treatment.
Since ctDNA can be detected from regular peripheral
blood samples, the detection of ctDNA could be a
promising, minimally invasive addition to the evalu-
ation of treatment response and prognosis in esopha-
geal cancer patients.
Study aim
As the aforementioned modalities do not individually
fulfill the requirements to justify treatment decision
making, the primary aim of the current study is to de-
velop a multimodal prediction model that predicts the
patients’ individual probability of a pCR after nCRT for
esophageal cancer. Accurate prediction of the response
to nCRT could lead to a patient-tailored approach with
omission of surgery in the future in case of predicted pCR,
potentially improving quality of life and reducing health
care costs. Furthermore, additional neoadjuvant treatment
could be offered to patients in case of non-pCR.
Methods
Objectives
The primary objective of the study is to develop a multi-
modal prediction model that predicts a patients’ individual
probability of a pathologic complete response to nCRT in
esophageal cancer by integrating DW-MRI, DCE-MRI
and 18F-FDG PET-CT scans acquired prior to, during and
after administration of nCRT.
The secondary objectives are as follows:
 To evaluate the accuracy of the multimodal prediction
model as developed under the primary objective for
the prediction of a pathologic good response
(i.e. tumor regression grade [TRG] 1 or TRG 2).
 To evaluate the effectiveness and efficacy of an
endoscopic and endosonographic assessment after
nCRT for the detection of residual disease, in
relation to the response classification as predicted by
the model developed under the primary objective.
 To evaluate the presence of, and changes in, ctDNA
during nCRT as a biomarker for a patients’ response
to nCRT, the detection of residual disease after
nCRT and progression-free and overall survival.
 To evaluate the accuracy of the multimodal
prediction model as developed under the primary
objective with addition of the endoscopic and
endosonographic assessment, and the ctDNA
measurements for the prediction of pCR and
pathologic good response (i.e. TRG 1 or TRG 2).
 To evaluate the accuracy of a visual assessment for
the detection of residual disease after nCRT based
on MRI and 18F-FDG PET-CT.
 To evaluate the performance of MRI and 18F-FDG
PET-CT imaging parameters for the prediction of
progression-free and overall survival.
Study design
The PRIDE study is a prospective, multi-center observa-
tional study with participation of 4 high-volume centers in
the Netherlands (University Medical Center Utrecht, The
Netherlands Cancer Institute - Antoni van Leeuwenhoek
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Hospital, University Medical Center Groningen and
Amsterdam University Medical Centers). Patients will
be informed and included at the outpatient depart-
ment at one of these investigational centers. The study
has been approved by the Medical Ethics Review Commit-
tee of the University Medical Center Utrecht (17–941,
NL62881.041.17). All participating hospitals gave their
consent after assessment of local feasibility. Written,
voluntary, informed consent to participate in the study
will be obtained from all patients.
Study population
In order to be eligible to participate in this study, a
patient must be scheduled to receive nCRT for a poten-
tially resectable, locally advanced (cT1b-4aN0-3 M0)
esophageal or gastroesophageal junction tumor, either
squamous cell carcinoma or adenocarcinoma. Neoadju-
vant chemoradiotherapy will be delivered according to
the CROSS-regimen [4], consisting of weekly adminis-
tration of carboplatin (doses titrated to achieve an area
under the curve of 2 mg per milliliter per minute) and
paclitaxel (50 mg per square meter of body-surface area)
for 5 weeks and concurrent radiotherapy (41.4 Gy in 23
fractions, delivered 5 days per week on workdays with
intensity modulated radiotherapy) followed by esopha-
gectomy after 8–10 weeks. Primary diagnosis and staging
will be based on endoscopy, EUS, 18F-FDG PET-CT and
histopathological evaluation of a tumor biopsy.
Patients who meet exclusion criteria for MRI or for
intravenous gadolinium-based contrast, patients with a
blood plasma glucose concentration > 10 mmol/L or
poorly controlled diabetes mellitus, patients with a status
after endoscopic mucosal resection (EMR) or endoscopic
submucosal dissection (ESD) of the primary tumor prior
to the start of nCRT, patients younger than 18 years and
pregnant or breast-feeding patients are not eligible.
Study protocol
A schematic representation of the study protocol is
depicted in Fig. 1. Patients will undergo standard diag-
nostic work-up and staging for esophageal cancer, in-
cluding a baseline 18F-FDG PET-CT (PET-CTpre). After
informed consent and before the start of nCRT, a base-
line MRI (MRIpre) is performed. A second MRI (MRIper)
and 18F-FDG PET-CT (PET-CTper) will be performed
during the third week of nCRT (after 10–15 fractions of
radiotherapy). A third MRI (MRIpost) will be performed
6–8 weeks after the completion of nCRT, and no sooner
than within 2 weeks before the intended date of surgery.
The third 18F-FDG PET-CT (PET-CTpost) is usual care
in all participating centers, and will be performed within
the same timeframe as the MRIpost. Blood samples will
be acquired at 3 time points, i.e. before, during and after
nCRT, to evaluate the presence of, and changes in
circulating tumor DNA (ctDNA). Furthermore, patients
will be asked to undergo an additional endoscopic assess-
ment after nCRT, PET-CTpost and MRIpost, within 2 weeks
prior to surgery. Surgical resection will be performed
8–10 weeks after completion of nCRT.
In summary, for study purposes patients will undergo 3
additional MRI scans (MRIpre, MRIper, MRIpost), 1 add-
itional 18F-FDG PET-CT scan (PET-CTper), blood samples
at 3 time points and 1 postchemoradiation endoscopic
and endosonographic assessment. The 18F-FDG PET-CT
scans before start of nCRT and after nCRT (PET-CTpre
and PET-CTpost) are standard of care in all participating
centers and will also be used for study purposes. All study
related procedures will take place before surgery.
MRI
Patients will undergo anatomical (T2-weighted [T2W])
and functional MRI (DWI and DCE) in one scanning
session every time. Two DWI series and one DCE scan
will be acquired. The sagittal DWI series (sagittal intra-
voxel incoherent motion [sIVIM] with 13 b-values: 0, 10,
20, 30, 40, 50, 75, 100, 200, 350, 500, 650 and 800 s/mm2)
will be used for quantitative analyses but also for the visual
assessment. Transversal DWI series (high resolution
tDWI, b-values: 0 and 800 s/mm2)will mostly be used for
visual assessments. The DCE-MRI scans will be acquired
with a temporal resolution of 3 s and the injection of a
gadolinium-based contrast agent. ADC and AUC values of
the various time points will be used as quantitative
measures of the DWI and DCE series, respectively.
Extensive effort has been put in the standardization
of MRI scan sequences by imaging experts and the
exchange of test scans.
18F-FDG PET-CT
The PET-CT examinations will be performed according
to EARL guidelines (European Association of Nuclear
Medicine) [29]. 18F-FDG is the tracer that will be used
for the assessment of abnormal glucose metabolism in
the tumor. On the 18F-FDG PET-CT scans, standardized
uptake volumes (SUVmax, SUVmean) and the total lesion
glycolysis (TLG) will be measured to quantify changes
over time in the glucose metabolism of the tumor.
Postchemoradiation endoscopic assessment
Patients will be asked to undergo a postchemoradiation
endoscopic assessment, consisting of an additional en-
doscopy with (random) bite-on-bite biopsies of the pri-
mary tumor site and other suspected lesions in the
esophagus, as well as endosonography with fine needle
aspiration of suspected lymph nodes after completion of
nCRT. This is an optional study procedure and patients
can choose to opt-out for this additional procedure.
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The endoscopic reevaluation will be performed by 1
or 2 experts in each of the 4 centers, to ensure high
quality and uniform procedures and to reduce the im-
pact of operator dependency. Furthermore, video re-
cordings of all patients with negative biopsies that
showed visual abnormalities of any kind during the
endoscopic procedure will be reevaluated by an expert
panel that will be blinded for the pathological out-
come of the resection specimen in order to investigate
whether a qualitative assessment of an expert team
can help to correctly identify residual tumor in pa-
tients with a negative biopsy.
Blood samples
Blood samples will be used to evaluate the presence of
ctDNA and changes in ctDNA concentrations since the
release of ctDNA within a patient during the course of
chemoradiotherapy has recently been demonstrated to
be a dynamic process [30]. To allow molecular analysis
of liquid biopsies, blood will be collected in cell-free
DNA collection tubes. The plasma will be aliquoted after
2 centrifugation steps and will be stored at − 80 °C [31].
This will allow isolation of ctDNA and subsequent mu-
tation analysis by means of Next Generation Sequencing
(NGS) at a later stage.
Surgery
A transthoracic or transhiatal esophagectomy will be
performed in all patients, depending on patient charac-
teristics, tumor localization, and local preference. Open,
hybrid and completely minimally invasive techniques are
allowed. Resection of the primary tumor and regional
lymph nodes will be carried out according to the current
requirements for esophageal cancer surgery in the
Netherlands [32]. For correct TNM-staging, the lymph
Fig. 1 Study design
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node dissection should contain at least 15 nodes derived
from both the mediastinum and upper abdomen.
Histopathological assessment
The resection specimen will be evaluated meticulously
according to a standardized protocol (tumor type and
extension, lymph nodes, resection margins) by a dedi-
cated pathologist with gastrointestinal subspecialty in
each center. The pathologist will be blinded for the re-
sults of the MRI and PET-CT exams. The most recent
edition of the UICC (International Union Against Cancer)
protocol will be used for TNM-classification and stage
grouping [33]. Special attention will be given to reporting
the effects of nCRT in the resection specimen. The (esti-
mated) location of the primary lesion plus surrounding
areas and other suspected lesions in the esophagus will be
embedded in order to adequately judge the presence of
residual tumor and treatment effects. The percentage of
viable tumor cells will be scored microscopically (ranging
from 0 to 100%), which directly corresponds to a stage in
either of the two most often used grading systems: ‘TRG 1
to 4’ [34] or the ‘Mandard score 1 to 5’ [35]. Therapy ef-
fects include necrosis, inflammation with multinucleated
giant cells, fibrosis and calcifications. Fibrosis is the most
remarkable effect and is used to estimate the extension of
the tumor before treatment. Lastly, all resection speci-
mens with TRG 1–2 will be revised by a second expert
pathologist.
Follow-up
Patients will remain in follow-up for 5 years after sur-
gery, according to local follow-up policies. The general
follow-up guideline in the Netherlands consists of rou-
tine follow-up visits every 3 months during the first year
after surgery. In the second year, follow-up takes place
every 6 months, and then yearly until 5 years after surgery.
Diagnostic investigations are generally only performed on
indication [32].
Study outcomes
The primary outcome of this study is the performance of
the multimodal prediction model for the correct predic-
tion of a patients’ individual probability of a pCR to nCRT
based on DW-MRI, DCE-MRI and 18F-FDG PET-CT
scans acquired prior to, during and after administration of
nCRT. Secondary outcome parameters include the per-
formance of the model for good response (i.e. TRG 1 and
TRG 2), the effectiveness and efficacy of a postchemora-
diation endoscopic and endosonographic assessment for
pCR prediction, the value of ctDNA as a biomarker for a
patients’ response to nCRT, progression-free and overall
survival, the performance of the model including results
from the endoscopic and endosonographic assessment
and ctDNA measurements for pCR and good response
prediction, the performance of a visual assessment for the
detection of pCR after nCRT based on MRI and 18F-FDG
PET-CT, and lastly the performance of the model for
prediction of progression-free and overall survival.
Statistical analysis
Data analysis of primary study objective
The analysis regarding the primary objective of this pro-
ject will have pCR as the predicted outcome of interest.
Statistical analysis and reporting will be performed in
accordance with the Standards for the Reporting of
Diagnostic accuracy studies (STARD) statement, and the
Transparent Reporting of a multivariable prediction model
for Individual Prognosis or Diagnosis (TRIPOD) statement
[36, 37]. The assessor(s) of the MRI and PET-CT images
will be blinded for the histopathological outcome.
A multivariable logistic regression model will be devel-
oped with pCR as dichotomous outcome measure. Many
of the imaging parameters are likely highly correlated
and provide similar (non-additional) information, par-
ticularly within one modality. The most valuable imaging
parameters within one imaging modality (i.e. within
DW-MRI, DCE-MRI and PET-CT imaging parameters)
will be entered in the model, based on the results of
previous knowledge. To determine whether the imaging
modalities provide complementary value in the predic-
tion of pCR, models will be compared based on Akaike’s
Information Criterion (AIC).
Model discrimination and calibration results will be
evaluated for the multivariable logistic regression models
using receiver operating characteristic (ROC) curve ana-
lysis with area-under-the-curve (AUCROC) estimates and
visual inspection of model calibration plots, respectively.
Internal validation using the bootstrap method with
1000 repetitions will be carried out to provide insight
into potential over-fitting and optimism in model per-
formance. Bootstrapping will allow for calculation of
bias-corrected c-indexes of the prediction model, and
provides shrinkage factors that can be used to adjust the
estimated regression coefficients in the model for over-
fitting and miscalibration. Sensitivity analyses will be
performed excluding one participating center each time
to study the influence of the multicenter study design on
the model performance.
Data analysis of secondary study objectives
ROC curve analysis with AUCROC estimates will be used
to determine the additional value of the postchemoradia-
tion endoscopic and endosonographic assessment and the
ctDNA measurements to the model as developed under
the primary objective, as well as the accuracy of the multi-
modal prediction model for the prediction of pathologic
good response (i.e. combined TRG 1 and TRG 2).
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The performance of a visual assessment for the detec-
tion of pCR after nCRT will be analyzed by calculation
of diagnostic performance measures such as sensitivity,
specificity, positive predictive value, negative predictive
value and accuracy (including corresponding 95% con-
fidence intervals). This also applies to the individual
performance of the endoscopic and endosonographic
assessment for the detection residual disease, as well
as for the performance of ctDNA measurements.
Multivariable Cox regression models will be used to
analyze the performance of the prediction model as devel-
oped under the primary objective, MRI and 18F-FDG
PET-CT imaging parameters, and ctDNA measurements
for the prediction of progression-free and overall survival.
Sample size calculation
It is conservatively assumed that adenocarcinoma and
squamous cell carcinoma need separate modeling and a
priori stratification. Based on 3 independent imaging pre-
dictors (e.g. a DW-MRI imaging parameter such as ΔADC,
a DCE-MRI imaging parameter such as ΔAUC and a
18F-FDG PET-CT imaging parameter such as ΔSUVmax),
this requires 30 events for both histopathological subtypes,
according to the ‘1 predictor per ~10 events’ rule-of-thumb
in logistic regression analysis [38, 39]. The CROSS-trial
demonstrated a pCR rate of 23% and 49% after nCRT for
patients with adenocarcinomas and squamous-cell carcin-
omas respectively [4]. According to the 1 in 10 rule, this
translates in a total accrual of at least 130 adenocarcinoma
patients and at least 61 squamous-cell carcinoma patients.
In case of an unexpected aberrant distribution of patients
that leads to decreased pCR rates, the aim is an accrual of
200 patients.
Discussion
Currently, groups of patients with esophageal cancer fit
in certain protocolled treatment approaches, but the
treatment is rarely a perfect fit for the individual patient.
The PRIDE study investigates whether a multimodal
image-guided model can be developed that accurately
predicts a patients’ individual histopathological response
to nCRT. Such a model would enable personalized treat-
ment for patients with esophageal cancer. Recent studies
indicate that an organ-sparing approach might be feas-
ible in selected patients with esophageal cancer who
have a pCR after nCRT [40–42]. However, satisfactory
diagnostic strategies to select these pathologic complete
responders are lacking up to now. Therefore, surgical re-
section after nCRT remains the most optimal curative
treatment in terms of survival in patients with locally
advanced esophageal cancer. If the PRIDE concept pro-
vides high predictive performance for pCR, this could
potentially lead to a new standard of care with direct
benefits to esophageal cancer patients. Furthermore,
accurate identification of the non-responders may be
beneficial, as these patients might benefit from alterna-
tive treatment strategies, such as additional neoadjuvant
treatment, or ineffective therapy could be stopped in this
group.
In the current study protocol, strict time points are
chosen for the MRI and 18F-FDG PET-CT imaging, as
well as for the blood samples and endoscopic assess-
ment. This way, a homogeneous cohort will be created,
in which measurement variability will be reduced as
much as possible. This is also reflected in the extensive
effort of the participating centers to standardize the
imaging protocols.
Since therapy effects continue to develop after treat-
ment, previous studies have underlined that MRI and
PET-CT imaging during nCRT as well as after nCRT for
esophageal cancer can function as predictors for pCR
[18, 43–46]. As such, the MRIpost and PET-CTpost scans
should be as close to the histopathological assessment of
the outcome (pCR) as possible, in order to make sure
that the findings on the MRIpost and PET-CTpost will
represent the histopathology accurately. This will likely
also prevent false positive results caused by transient
radiation-induced esophagitis, which is known to de-
crease over time after nCRT. Therefore, the chosen time
points in our study include scans before the start of
nCRT (MRIpre/PET-CTpre), scans during the third week
of nCRT (MRIper/PET-CTper), and scans within 2 weeks
before surgery (MRIpost/PET-CTpost). In patients under-
going an additional endoscopic and endosonographic
assessment, this will be intended after the 18F-FDG
PET-CTpost and the MRIpost, but prior to surgery. If an
organ-sparing approach is eventually implemented in
clinical practice for predicted complete responders, an
endoscopic confirmation without signs of residual tumor
will most likely be required.
Of note, two studies, namely the Dutch SANO trial
[47] and the French ESOSTRATE trial (ClinicalTrials.-
gov identifier NCT02551458), are currently studying ac-
tive surveillance strategies after nCRT for patients with a
clinical complete response. For the SANO trial, a clinical
complete response is based on 18F-FDG PET-CT and en-
doscopy with at least 8 (random) bite-on-bite biopsies.
These studies together will include a total of 600 pa-
tients (300 within each trial) and the primary outcome
of these studies is survival. In contrast to these trials, the
current study involves the careful development of an
accurate image-guided response evaluation strategy to
predict pCR in an observational study, without the sim-
ultaneous implementation of postponed surgical resec-
tion in clinical complete responders that might harm the
patient. The results of this study will therefore play an
important role in the accurate identification of esopha-
geal cancer patients with a pCR to nCRT who could
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benefit from an organ-sparing approach in the future.
Ultimately, the results of the three trials together could
lead to a patient-tailored wait-and-see approach with
omission of surgery in the appropriate patients.
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